Antineoplastic Properties of Bacteriocins: Revisiting Potential Active Agents

Bacteriocins are antimicrobial peptides produced by a wide range of bacteria. Their antineoplastic properties have been inadequately revealed in the late 70s by using crude bacteriocin preparation toxic to mammalian cells. Nowadays, purified bacteriocins are available and have shown inhibitory properties toward diverse neoplastic line cells. Pyocin, colicin, pediocin, and microcin are among bacteriocins reported to present such activity. Moreover, modified bacteriocins proved to be effective in a glioblastoma xenograft mouse model. Screening for the presence of bacteriocin in colon cancer subjects has been studied with mixed results. Bacteriocin use as a therapeutic agent or in a prevention setting is discussed specifically evaluating bacteriocins biochemical properties and recent advances in peptide therapeutics.

[1]  B. Houben,et al.  Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction. , 2007, Oral microbiology and immunology.

[2]  D. Archambault,et al.  Partial characterization of bacteriocins produced by human Lactococcus lactis and Pediococccus acidilactici isolates , 2007, Journal of applied microbiology.

[3]  Z. Pei,et al.  Bacteria, inflammation, and colon cancer. , 2006, World journal of gastroenterology.

[4]  T. Fukushima,et al.  Anti-tumor activity of de novo designed small globular protein (SGP) in vivo. , 2006, Anticancer research.

[5]  B. Kirkup,et al.  Bacteriocins as oral and gastrointestinal antibiotics: theoretical considerations, applied research, and practical applications. , 2006, Current medicinal chemistry.

[6]  D. Hoskin,et al.  Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment , 2006, Expert opinion on investigational drugs.

[7]  V. Steele,et al.  Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. , 2006, Cancer research.

[8]  T. Falla,et al.  Antimicrobial peptides: therapeutic potential , 2006, Expert opinion on pharmacotherapy.

[9]  S. B. Nascimento,et al.  Bacteriocins as alternative agents for control of multiresistant staphylococcal strains , 2006, Letters in applied microbiology.

[10]  Bernd Groner,et al.  Current strategies for the development of peptide‐based anti‐cancer therapeutics , 2005, Journal of peptide science : an official publication of the European Peptide Society.

[11]  R. P. Ross,et al.  Food microbiology: Bacteriocins: developing innate immunity for food , 2005, Nature Reviews Microbiology.

[12]  F. Pierre,et al.  How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. , 2005, European journal of cancer.

[13]  V. Tjomsland,et al.  Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer. , 2005, International journal of oncology.

[14]  L. Dicks,et al.  Mode of action of lipid II-targeting lantibiotics. , 2005, International journal of food microbiology.

[15]  J.H. Kang,et al.  Characterization of a bacteriocin produced by Enterococcus faecium GM‐1 isolated from an infant , 2005, Journal of applied microbiology.

[16]  Y. Sanz,et al.  Production of bacteriocin-like inhibitory compounds by human fecal Bifidobacterium strains. , 2005, Journal of food protection.

[17]  M. Riley,et al.  Genetically engineered bacteriocins and their potential as the next generation of antimicrobials. , 2005, Current pharmaceutical design.

[18]  W. A. van der Donk,et al.  Biosynthesis and mode of action of lantibiotics. , 2005, Chemical reviews.

[19]  B. E. Davidson,et al.  Novel Expression System for Large-Scale Production and Purification of Recombinant Class IIa Bacteriocins and Its Application to Piscicolin 126 , 2004, Applied and Environmental Microbiology.

[20]  A. Deezagi,et al.  Cytotoxic effects of pyocin S2 produced by Pseudomonas aeruginosa on the growth of three human cell lines. , 2004, Canadian journal of microbiology.

[21]  Microbial-gut interactions in health and disease. Gastrointestinal cancer. , 2004, Best practice & research. Clinical gastroenterology.

[22]  J. M. Rodríguez,et al.  Heterologous production of bacteriocins by lactic acid bacteria. , 2003, International journal of food microbiology.

[23]  D. Richardson,et al.  The role of iron in cell cycle progression and the proliferation of neoplastic cells. , 2002, Biochimica et biophysica acta.

[24]  Y. Michel-Briand,et al.  The pyocins of Pseudomonas aeruginosa. , 2002, Biochimie.

[25]  H. Sahl,et al.  Mode of action of modified and unmodified bacteriocins from Gram-positive bacteria. , 2002, Biochimie.

[26]  Keun-Hyeung Lee.  Development of short antimicrobial peptides derived from host defense peptides or by combinatorial libraries. , 2002, Current pharmaceutical design.

[27]  C. Hetz,et al.  Microcin E492, a channel-forming bacteriocin from Klebsiella pneumoniae, induces apoptosis in some human cell lines , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Kok,et al.  Pediocin PA-1, a Wide-Spectrum Bacteriocin from Lactic Acid Bacteria , 2002, Critical reviews in food science and nutrition.

[29]  J. Primrose.  Treatment of colorectal metastases: surgery, cryotherapy, or radiofrequency ablation , 2002, Gut.

[30]  J. Šmarda,et al.  Incidence of colicinogenic strains among human Escherichia coli , 2001, Journal of basic microbiology.

[31]  R. Farías,et al.  Escherichia coli RNA Polymerase Is the Target of the Cyclopeptide Antibiotic Microcin J25 , 2001, Journal of bacteriology.

[32]  R. P. Ross,et al.  Lantibiotics: structure, biosynthesis and mode of action. , 2001, FEMS microbiology reviews.

[33]  C. Walsh,et al.  The antibiotic microcin B17 is a DNA gyrase poison: characterisation of the mode of inhibition. , 2001, Journal of molecular biology.

[34]  V. Eijsink,et al.  Engineering Increased Stability in the Antimicrobial Peptide Pediocin PA-1 , 2000, Applied and Environmental Microbiology.

[35]  E. Parente,et al.  Production, recovery and purification of bacteriocins from lactic acid bacteria , 1999, Applied Microbiology and Biotechnology.

[36]  R B Hill,et al.  The interaction between RTX toxins and target cells. , 1999, Trends in microbiology.

[37]  A. Driessen,et al.  Bacteriocins: mechanism of membrane insertion and pore formation , 1999, Antonie van Leeuwenhoek.

[38]  P. Cornelis,et al.  Uptake of Pyocin S3 Occurs through the Outer Membrane Ferripyoverdine Type II Receptor of Pseudomonas aeruginosa , 1999, Journal of bacteriology.

[39]  P. Hernández,et al.  Detection of enterocin AS-48-producing dairy enterococci by dot-blot and colony hybridization , 1998, Journal of Dairy Research.

[40]  B. Ray.  Fundamental Food Microbiology , 1996 .

[41]  R. Evans,et al.  Applications of the bacteriocin, nisin , 1996, Antonie van Leeuwenhoek.

[42]  W. D. de Vos,et al.  Improvement of solubility and stability of the antimicrobial peptide nisin by protein engineering , 1995, Applied and environmental microbiology.

[43]  B. Rosen,et al.  The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Kobayashi,et al.  Functional domains of S-type pyocins deduced from chimeric molecules , 1993, Journal of bacteriology.

[45]  T. Klaenhammer,et al.  Genetics of bacteriocins produced by lactic acid bacteria. , 1993, FEMS microbiology reviews.

[46]  M. Yuan,et al.  Partially purified bacteriocin kills malignant cells by apoptosis: programmed cell death. , 1992, Cellular and molecular biology.

[47]  A. W. Smith,et al.  The pyocin Sa receptor of Pseudomonas aeruginosa is associated with ferripyoverdin uptake , 1992, Journal of bacteriology.

[48]  R. Hill,et al.  Further studies of the action of a partially purified bacteriocin against a murine fibrosarcoma. , 1991, Cancer research.

[49]  C. Hernández-Chico,et al.  The peptide antibiotic microcin B17 induces double‐strand cleavage of DNA mediated by E. coli DNA gyrase. , 1991, The EMBO journal.

[50]  V. Lorenzo.  Isolation and characterization of microcin E 492 fromKlebsiella pneumoniae , 1984, Archives of Microbiology.

[51]  T. Watanabe,et al.  Mycobacteriocins produced by rapidly growing mycobacteria are Tween-hydrolyzing esterases , 1983, Journal of bacteriology.

[52]  H. Saito,et al.  Effects of a Bacteriocin from Mycobacterium smegmatis on BALB/3T3 and Simian Virus 40‐Transformed BALB/c Mouse Cells , 1981, Microbiology and immunology.

[53]  H. Saito,et al.  Effect of a bacteriocin produced by Mycobacterium smegmatis on growth of cultured tumor and normal cells. , 1979, Cancer research.

[54]  J. Šmarda,et al.  Effect of colicin E3 on leukemia cells P 388 in vitro , 1979, Experientia.

[55]  D. Fumarola.  Bacteriocins as cytotoxic agents against tumors: the role of possible contaminants. , 1978, Bollettino dell'Istituto sieroterapico milanese.

[56]  R. Cheung,et al.  Bacterial proteinaceous products (bacteriocins) as cytotoxic agents of neoplasia. , 1976, Cancer research.

[57]  J. Šmarda,et al.  Human tumor cells are selectively inhibited by colicins , 2008, Folia Microbiologica.

[58]  J. Šmarda,et al.  The cytotoxic and cytocidal effect of colicin E3 on mammalian tissue cells , 2008, Folia Microbiologica.

[59]  J. Šmarda,et al.  Cytotoxic effects of colicins E1–E5 and K on hamster fibroblasts , 2008, Folia Microbiologica.

[60]  M. Rodnina,et al.  Colicins and their potential in cancer treatment. , 2007, Blood cells, molecules & diseases.

[61]  S. Agelaki,et al.  Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: A phase II trial. , 2005, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[62]  Yuan-Kun Lee,et al.  Microflora of the gastrointestinal tract: a review. , 2004, Methods in molecular biology.

[63]  R. Labianca,et al.  Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  J. Šmarda,et al.  Cytotoxic effects of colicins E1 and E3 on v-myb-transformed chicken monoblasts. , 2001, Folia biologica.

[65]  I. Nes,et al.  Class II antimicrobial peptides from lactic acid bacteria. , 2000, Biopolymers.

[66]  J. Tagg.  Bacteriocins of Gram-Positive Bacteria: An Opinion Regarding their Nature, Nomenclature and Numbers , 1992 .

[67]  C. Musclow,et al.  Bacteriocin receptors on malignant mammalian cells: are they transferrin receptors? , 1986, Cellular and molecular biology.

[68]  V. de Lorenzo.  Isolation and characterization of microcin E492 from Klebsiella pneumoniae. , 1984, Archives of microbiology.